Who are Carbocaine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Phenurone, Ropivacain, Lamictal, Carbocaine, Keppra, Naropeine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mepivacaine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Carbocaine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Carbocaine (MEPIVACAINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amide Local Anesthetic. Area: Pain.

marketed Amide Local Anesthetic Sodium channel protein type 1 subunit alpha Pain Small molecule Live · refreshed every 30 min

Target snapshot

Carbocaine (MEPIVACAINE) — Eastman Kodak.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carbocaine TARGET	MEPIVACAINE	Eastman Kodak	marketed	Amide Local Anesthetic	Sodium channel protein type 1 subunit alpha	1960-01-01
Phenurone	PHENACEMIDE	Abbvie	marketed		Sodium channel protein type 1 subunit alpha	1951-01-01
Ropivacain	Ropivacain	University Hospital, Basel, Switzerland	marketed		Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
Lamictal	lamotrigine	GSK	marketed	Anti-epileptic Agent [EPC]	5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha
Carbocaine	Carbocaine	Nantes University Hospital	marketed		Sodium channel protein type 1 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha
Keppra	Keppra	Masonic Cancer Center, University of Minnesota	marketed		Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A
Naropeine	Naropeine	University Hospital, Rouen	phase 3		Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-01-07 — Lamictal · 8637512 · Formulation · US
2040-05-29 — Lamictal · 11596634 · Method of Use · US
2040-05-29 — Lamictal · 11612566 · Method of Use · US

Sponsor landscape (Amide Local Anesthetic class)

· 1 drug in this class
Eastman Kodak · 1 drug in this class
Fresenius Kabi · 1 drug in this class
Innocoll · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Carbocaine — Competitive Intelligence Brief. https://druglandscape.com/ci/mepivacaine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing